Medical Bureau of Road Safety annual report 2018. by unknown
MEDICAL BUREAU OF ROAD SAFETY, HEALTH SCIENCES 
CENTRE, UNIVERSITY COLLEGE DUBLIN, BELFIELD, DUBLIN 4
MEDICAL BUREAU
OF ROAD SAFETY
ANNUAL REPORT 2018

TABLE OF CONTENTS
Director’s Introduction  ...............................................1
50 Year Celebration  .................................................... 2
Mission .......................................................................... 4
Functions of the Medical Bureau of 
Road Safety   ................................................................ 5
Achievements and Developments  ........................... 7
Specimens Received in the Laboratory 
for Analysis ................................................................... 9
Alcohol Programme: Blood and Urine  ................... 13
Alcohol Programme: Breath .................................... 16
Toxicology Programme  ............................................ 21
Quality Assurance .....................................................28
Profi ciency Testing Programme...............................29
Financial Information & Corporate 
Governance ................................................................30
Statement on Internal Control ................................33
Freedom of Information ...........................................35
Staffi ng .......................................................................35
MBRS Organisational Chart .....................................36
Conferences and Courses attended 
by Staff in 2018 .......................................................... 37
Energy Consumption.................................................39
Legal Disclaimer ........................................................39
d Medical Bureau of Road Safety Annual Report 2018
Medical Bureau of Road Safety Annual Report 2018 1
This Annual Report for the 50th Anniversary year sets out a summary of the activities and 
performance of the Medical Bureau of Road Safety, together with important and relevant 
information and data in the area of driving under the influence of intoxicants and also the 
Bureau’s ongoing core and integral role in the Road Safety Strategy 2013 – 2020.   
The Bureau was established in 1968 and in its 50 years of existence its mission has been to 
provide a high quality national forensic service in intoxicant detection thus supporting the 
effective operation of road traffic legislation passed by the Oireachtas.  There has been an 
enormous improvement in roads safety in recent decades.    In 1998 Ireland had 124 road 
traffic deaths per million of the population and this reduced to 30 in 2018, the second 
lowest rate in the European Union.   The Bureau has been one of the core contributors to 
this improvement together with its partners in the Department of Transport, Tourism and 
Sport, the Road Safety Authority, An Garda Síochána and other organisations and bodies. 
It has continued to contribute to the Ministerial Committee on road safety and at RSA and 
Garda road safety launches as well as playing its role at international level on committees 
and conferences in many countries.   
The preliminary drug testing programme completed its first full year in 2018 with 157 
Dräger DrugTest 5000 devices provided to the Gardaí for mandatory intoxicant testing 
checkpoints and 87 garda stations.   The roll out of the new Dräger 7510 preliminary 
alcohol breath testing devices commenced in October 2018 with a total of 625 devices 
provided to the Gardaí with the remaining 775 devices to be provided in the first half of 
2019.   
The number of blood and urine specimens received for alcohol analysis increased by 
14% over 2017 and the corresponding figure for toxicology analysis was a 34% increase. 
There was a 9% increase in evidential breath testing numbers.  These significant 
increases have been a challenge which the Bureau addressed successfully in the year. 
Training and information support continued to be provided for An Garda Síochána, the 
Prosecution Services, Doctors and Pharmacists.   The Bureau continued to be involved in 
proficiency testing programmes with a number of providers for a large number of analytes 
throughout the year and also continued its successful accreditation with the Irish National 
Accreditation Board for its wide variety of laboratory testing functions.
In October the Bureau marked its 50th Anniversary with a celebration and academic 
meeting opened by Mr. Shane Ross T.D., Minister for Transport, Tourism and Sport 
and Professor Andrew Deeks, President of University College Dublin emphasising the 
continuing strong links between the two organisations since the establishment of the 
Bureau.  The academic programme included international and national speakers and was 
attended by representatives from the Bureau’s many partner organisations.  The Bureau 
now looks forward to its next fifty years.
Professor Denis A. Cusack
Director
Directors Introduction
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50 YEAR CELEBRATION
The Medical Bureau of Road Safety was 
established under the Road Traffi c Act 1968 in 
November of that year. The Board of the Bureau 
held its Inaugural Meeting on 2nd December 
1968. 
On Thursday 18th October 2018 the Medical 
Bureau of Road Safety held a ceremony to 
mark 50 years at the frontline of forensic road 
safety nationally and internationally from 1968 
– 2018. It commenced with the unveiling of a 
celebratory plaque by Shane Ross, TD, Minister 
for Transport, Tourism and Sport and Professor 
Andrew Deeks, President of University College 
Dublin.
Opening remarks were made by the MBRS Chair, 
Dr. Declan Bedford. This was followed by a 
number of presentations on intoxicated driving, 
road safety and court proceedings over the past 
50 years. There were representatives from the 
Road Safety Authority and An Garda Síochána in 
attendance.
The Keynote Speaker was Professor Eilish 
Gilvarry from the UK followed by Professor 
Denis Cusack, Director Medical Bureau of Road 
Safety, Ms. Helen Kearns, MBRS, Dr Richard 
Maguire, MBRS and Ms. Stephanie O’Brien, 
Offi ce of the Director of Public Prosecutions. 
L – R: Mr. Michael McDermott, MBRS Board Member, Professor Denis Cusack, Director MBRS, Professor Andrew Deeks, 
President of University College Dublin, Shane Ross, TD, Minister for Transport, Tourism and Sport and Dr. Declan Bedford, 
MBRS Chair.
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L-R: Ms. Helen Kearns, Chief Analyst, MBRS, Ms. Stephanie O’Brien, Office of the Director of Public Prosecutions, Professor 
Denis Cusack, Director MBRS, Professor Eilish Gilvarry, Keynote Speaker, Dr. Richard Maguire, Principal Analyst, Toxicology, 
MBRS
L-R: Shane Ross, TD, Minister for Transport, Tourism and 
Sport, Ms. Moyagh Murdock, RSA, Chief Superintendent 
Aidan Reid, An Garda Síochána, Professor Andrew Deeks, 
President of University College Dublin
Dr. Declan Bedford, MBRS Chair.
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“To provide a high quality national forensic 
service in alcohol and drug (intoxicant) 
detection in support of the effective operation 
of the road traffi c legislation and contribution 
to road safety and medical fi tness to drive 
measures.”
MISSION STATEMENT: 
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FUNCTIONS OF THE MEDICAL 
BUREAU OF ROAD SAFETY
The responsibility for chemical testing of 
intoxicants in driving in Ireland rests with 
the Medical Bureau of Road Safety which is a 
corporate body established in November 1968 
by the Minister for Local Government under Part 
V of the Road Traffi c Act, 1968.  
The Minister’s title was altered to Minister for 
the Environment & Local Government on 22nd 
July 1997.  In June 2002 the Medical Bureau 
of Road Safety came under the aegis of the 
Minister for Transport under the Transfer of 
Departmental Administration and Ministerial 
Functions Order 2002.  
Since 2011 the Medical Bureau of Road Safety is 
under the Department of Transport, Tourism and 
Sport. The functions of the Bureau are laid down 
in the Road Traffi c Acts 1968 – 2016.
Research 
on drinking 
and drugs in 
relation to driving 
and development of 
forensic toxicology 
methods
Approval, 
supply and testing 
of equipment or
apparatus for 
determining 
the presence of 
drugs in oral fl uid
Approval, 
supply, testing 
of equipment 
or apparatus for 
indicating the presence 
/ determining the 
concentration of 
alcohol in the 
breath
Provision of 
equipment for the 
taking or provision of 
specimens of blood 
and urine
Issuing of 
Certifi cates of 
Analysis
Receipt and 
analysis for 
intoxicants of 
specimens of blood and 
urine forwarded to 
the Bureau
FUNCTIONS
OF THE MEDICAL 
BUREAU OF 
ROAD SAFETY
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When the Bureau was established in 1968 it 
commenced operating for Roadside Alcohol 
Testing, Blood and Urine Alcohol Analysis, the 
Issue of Certifi cates and provision of equipment 
for the taking of specimens (kits). 
There have been many legislative changes such 
as the introduction of evidential breath alcohol 
testing (EBT) and driving under the infl uence of 
drugs (DUID), specimens provided in hospitals, 
specimens taken from drivers involved in 
collisions and mandatory intoxicant testing to 
include Preliminary Breath Alcohol testing (PBT) 
and  Preliminary Drug Testing (PDT). The Bureau 
issues certifi cates under section 17 of the Road 
Traffi c Act 2010 (as amended 2016), certifying 
the concentration of alcohol in blood or urine, 
certifying the presence of a drug or drugs in 
blood or urine and certifying the concentration 
of a drug or drugs in blood. 
The Road Traffi c Act 2018 introduced a more 
severe penalty for drivers having alcohol levels 
between 50mg/100ml and 80mg/100ml blood 
and equivalent in urine or breath, recognizing 
that even at low levels of alcohol driving is 
impaired. 
The Bureau continued to expand and develop 
all aspects of its work while focusing on its legal 
responsibilities as set out in the Road Traffi c Acts 
(RTA) and in accordance with the Government’s 
Road Safety Strategy. 
The Bureau operates to fulfi ll the intertwined 
functions below.
The Bureau continues to keep up to date 
with technology and use the best methods of 
analysis. It has kept abreast of innovation in 
instrumentation in the fi eld of alcohol and drug 
detection both in the laboratory and outside of 
the laboratory – roadside and garda stations.
The Bureau provides a service to the 
Department of Transport, Tourism and Sport, the 
Courts, the Garda Síochána, both defence and 
prosecution lawyers and the public.
The continued successful operation of the 
Bureau is the investment in staff training and 
skill enhancement. The Director is responsible 
for the day to day running of the Bureau. 
The Chief Analyst is responsible for the 
day to day running of the laboratories and 
their programmes. Each programme has a 
programme manager at Principal Analyst level. 
The Senior Administrator is responsible for the 
Corporate/Financial programme and for overall 
administration within the Bureau. The Bureau 
has a Quality Manager at Principal Analyst level.
(see organisational chart on page 36)
Blood and Urine 
Alcohol Analysis
Oral Fluid Drug
Testing
Corporate and  
Financial
Breath Alcohol 
Analysis
Research – Driving 
under the infl uence of 
Intoxicants.
New Technologies.
Quality Assurance
Blood and Urine
Drug Analysis
Professional Expert 
Witness
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SIGNIFICANT ACHIEVEMENTS & 
DEVELOPMENTS DURING 2018
Preliminary Drug Testing
Preliminary Drug Testing (PDT) continued to 
increase at a moderate rate throughout the 
country. The PDT review group with members 
from the MBRS, AGS and DTTAS continued 
to meet to review and assess use and ensure 
continued support of the programme. 
Laboratory Preliminary Drug Screening
The Bureau implemented a new Preliminary 
Drug Screening method using LC-MS-MS for the 
analysis of drugs, this replaced the previously 
used immunoassay system. The new screening 
method allows the specifi c drug to be identifi ed 
at this preliminary stage rather than the class 
of drug which had been the case with the 
immunoassay test.
Confi rmatory Drug Testing
The Bureau continued to carry out all blood 
confi rmation testing in-house in 2018 and from 
May 2018 all urine confi rmatory testing was 
carried out in-house. 
Preliminary Breath Alcohol Testing
The Bureau commenced procurement for 
Roadside Breath Testing devices to include extra 
functionality to meet the requirements of An 
Garda Síochána. The initial procurement process 
was completed in December 2017 with the 
tender awarded in early 2018 to Dräger for the 
provision of preliminary breath testing devices; 
the Dräger 7510. The new devices have the 
same alcohol measurement capability but have 
extra functionality in terms of location tracking 
and data storage. A total of 1,400 devices will 
be deployed to An Garda Síochána.   A total of 
625 were deployed by the end of 2018 with the 
remainder to be issued in 2019.
Quality Assurance
ISO 17025 accreditation was maintained in 2018 
for the following tests:
› Blood and Urine Alcohol Analysis
› Evidential Breath Testing 
› Preliminary Breath Testing
› Preliminary Drug Testing
› Drug testing in Oral Fluid
› Laboratory Preliminary Drug Screening 
› Cannabis confi rmation in Blood and Urine
› Benzodiazepine confi rmation in Blood and 
Urine.
› Multidrug confi rmatory testing in Blood
Under fl exible scope multidrug confi rmatory 
testing in Urine was added to the list of 
accredited tests and was added to the scope 
of testing following auditing by INAB (Irish 
National Accreditation Board) in early 2019.
Health, Welfare and Safety
The Bureau reviewed its Safety Statement and 
continued to monitor all aspects of Health and 
Safety throughout 2018. All staff are made 
aware of their role with regard to Health, 
Welfare and Safety and a staff seminar on 
Dignity and Respect was held during 2018. There 
were no reportable or signifi cant accidents or 
incidents in the year.
Knowledge Sharing and Development
Bureau staff and the Director presented at 
and attended many conferences, meetings 
and working groups related to the work of the 
Bureau with the aim of sharing expertise and 
knowledge. 
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The Bureau also hosted several secondary 
school transition year students for a week each 
during 2018.
Bureau staff are involved in a LIMS (Laboratory 
Information Management System) user group 
along with other Public Service and Civil Service 
laboratories.  The Bureau hosted several of these 
meetings in 2018.
Bureau scientists sit on national and 
international standards and knowledge sharing 
committees and working groups including OIML 
(International Organisation of Legal Metrology), 
Eurachem, UKIAFT (United Kingdom and 
Ireland Association of Forensic Toxicologists) 
and EMCDDA (European Monitoring Centre for 
Drugs and Drug Addiction).
The Principal Analyst in Toxicology, the Director 
and Dr. Shane Cullinan (RCSI) published an 
article in the publication The Irish Pharmacist 
in 2018 entitled Drug Driving and the Irish 
Pharmacist.  
Garda Seminars
Senior Bureau staff provided various seminars to 
Garda groups as required throughout 2018.
Global Light of Hope Award 
The Director accepted the Global Light of Hope 
2017 award, Ambassador of the Year for Road 
Safety and Road Victims presented to him by 
the Irish Road Victims Association in March 
2018 and which he accepted as recognising the 
work of the staff of the Medical Bureau of Road 
Safety. 
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SPECIMENS RECEIVED IN THE 
LABORATORY FOR ANALYSIS
In 2018, a total of 3,865 blood and urine specimens were analysed for alcohol and/or drugs. 
There was a signifi cant increase in the number of samples being forwarded to the Bureau for analysis 
for the second year running since the implementation of the Road Traffi c Act 2016, which introduced 
Preliminary Drug Testing by An Garda Síochána and per se level testing for cannabis, cocaine and heroin. 
    *Note: Number of Specimens forwarded to the Bureau for analysis by An Garda Síochána
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n Specimens 2017 n  Specimens 2018
Programme 2018 2017 Increase
Alcohol Blood & Urine 3,865 3,386 14%
Toxicology Blood & Urine 2,152 1,592 34%
Evidential Breath Testing 6,021 5,512 9%
Table 1 Total Number of Specimens Received within Programmes
Chart 1 Blood & Urine Specimens by County 2017 v 2018*
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Chart 3 Time Specimen taken
Analysis of Time
Specimens of blood and urine are much more likely to be provided in the evening to early hours of the 
morning as can be seen from the chart below. This remains unchanged from previous years.
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Number of Specimens Provided in Hospitals
In 2018 there were 544 specimens provided in hospitals, this represents 14% of total blood and urine 
specimens. 
Unconscious Drivers
In 2018, 6 specimens were forwarded to the Bureau for analysis following blood draws from unconscious 
drivers.
Analysis of Day
From the chart below, it is evident that more specimens of blood and urine are provided on Saturday, 
Sunday and Monday. However, the time specimens are provided can also impact these figures; hence the 
levels indicated for Monday which could be early morning times.
25%
20%
15%
10%
5%
0%
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Chart 4 2018 Day Specimen Taken
Gender Analysis
A similar pattern was seen in the male/female ratio in 2018 compared to previous years with 83% of 
drivers providing specimens being male.
2018 2017
MALE 83% 82%
FEMALE 17% 18%
Table 2 Gender Profile of Specimens received – Blood & Urine
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Age Profi le
It is notable that the age profi le of drivers providing blood and urine specimens in the 25 – 34 year old 
bracket contribute to the greatest percentage of arrested drivers. There has been a steady increase in the 
contribution made by the drivers in the age 25-34 over the past four years but in the age category <25 
there has been a slight decrease.
Chart 5 2018 Age Profi le of Drivers
n <25, 18% n 25-34, 33%
n 35-44, 22%
n Not Stated, 1%
n 65+, 5%
n 55-64, 8%
n 45-54, 13%
Chart 6 2018 Age profi le of Drivers – Male v Female
35%
30%
25%
20%
15%
10%
5%
0%
<25 25-34 35-44 45-54 55-64 65+
n Male 16.8% 28.7% 17.8% 9.6% 5.4% 4.0%
n Female 1.6% 4.7% 4.1% 3.4% 2.1% 1.1%
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The main functions of the Blood and Urine 
programme are:
› The receipt and analysis of specimens of 
blood and urine forwarded to the Bureau 
› The determination of the concentration of 
alcohol in blood and urine specimens
› The issue of Certifi cates of Analysis
› The testing of spurious specimens
› Provision of expert assistance to the Courts 
and the Department of Transport, Tourism 
and Sport 
› Collection and analysis of data in relation to 
alcohol tests
Provision of Blood and Urine Kits 
The number of specimen kits prepared in 2018 was 2,900 (consisting of 1,500 blood kits and 1,400 urine 
kits.)
In total 4,100 kits were issued, comprising of 2,700 blood kits and 1,400 urine kits to Garda Central Stores 
in 2018.  
1,400 jugs were prepared and issued. (See Table 3). This was a decrease compared to recent years as 
suffi cient stock was already distributed in Garda Stations nationwide. 
Kits Prepared Kits Issued
2018 2017 2018 2017
BLOOD KITS 1,500 3,700 2,700 3,800
URINE KITS 1,400 3,200 1,400 3,200
JUGS 1,400 2,900 1,400 3,300
Table 3 Kits Prepared & Issued by the Medical Bureau of Road Safety
The Bureau retained a contingency supply of at least 500 of each kit type throughout the year.
ALCOHOL PROGRAMME: 
BLOOD & URINE
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Blood and Urine Alcohol Analysis
Blood and Urine specimens are analysed using Headspace Gas Chromatography with Flame Ionisation 
Detection (HSGC-FID). Each specimen is analysed at least twice by two different scientists using two 
different HSGC-FID systems. The results of analyses must concur before issue of a Certifi cate of Analysis. 
A total of 3,865 blood and urine specimens were received for analysis during 2018.  17 specimens were 
received for drug testing only as the drivers had been tested for alcohol using an Evidential Breath Testing 
instrument. In 77 (2%) cases, certifi cates were not issued either because of some defect in the specimen 
or in the documentation accompanying the specimen.  This level of “non-issue” is a slight decrease 
on 2017. The number of blood and urine specimens received in 2018 increased by 14% on the number 
received during 2017.
Mean Alcohol Level in Blood and Urine
The mean alcohol level in blood was 154mg/100ml and in urine was 192mg/100ml for 2018 excluding 
specimens which had no trace of alcohol.
The max alcohol level in blood was 463mg/100ml and in urine was 528mg/100ml for 2018.
Over Twice the Limit of 50mg/100ml** (Blood) or 67mg/100ml** (Urine)
During 2018 there were 1,518 specimens certifi ed which were two or more times over these limits. This 
fi gure represents 40% of the total number of specimens certifi ed. 
** It is important to note that on receipt of specimens for testing, the Bureau does not receive driver 
classifi cation details; i.e., Fully Licenced Drivers versus Professional, Learner and Novice Drivers where the 
legal limits are reduced.
Charts 7 and 8 show the proportion of drivers in the different bands for blood and urine respectively.
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Chart 7 Certifi ed Blood Alcohol Levels
60%
50%
40%
30%
20%
10%
0%
Nil <20 21-50 51-80 81-100 101-150 151-200 >200
n 2017 39% 1% 4% 5% 4% 13% 15% 19%
n 2018 52% 1% 4% 5% 3% 11% 13% 11%
Chart 8 Certifi ed Urine Alcohol Levels
30%
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20%
15%
10%
5%
0%
Nil <27 28-67 68-107 108-135 136-200 201-267 >268
n 2017 28% 2% 6% 9% 6% 17% 19% 12%
n 2018 25% 2% 6% 10% 6% 19% 18% 15%
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ALCOHOL PROGRAMME: 
BREATH
The main functions of the Breath Alcohol 
programme are:
› The approval, supply and testing of apparatus 
for indicating the presence of alcohol in the 
breath (roadside preliminary breath testing 
devices)
› The approval, supply and testing of apparatus 
for determining the concentration of alcohol 
in the breath (evidential breath testing 
instruments)
› Provision of expert assistance to the Courts 
and DTTAS (Department of Transport, 
Tourism and Sport).
› Provision of training courses for EvidenzerIRL 
Operators and Supervisors.
› Collection and analysis of data in relation to 
evidential breath alcohol tests.
Roadside Breath Alcohol Testing
The Bureau continued to support approximately 
1,100 Dräger 6510 electronic devices issued 
to An Garda Síochána in approximately 373 
Garda Stations throughout the country until the 
commencement of the Breath Screening Device 
replacement programme in October 2018. The 
replacement programme will be completed 
mid-2019. Both Dräger 6510 and Dräger 7510 
devices issued continue to be supported.
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Invitation to Tender
The Bureau, in conjunction with UCD 
Procurement, the Offi ce of Government 
Procurement and Education Procurement in U.L, 
issued an invitation to tender for the supply of 
Roadside Breath Alcohol Screening Devices in 
2017. These devices were to upgrade the Dräger 
6510 devices due to limited support on the older 
devices and the introduction of GPS and data 
download facility on the newer models. Some 
of the 6510 devices in use were over 10 years 
old. Four suppliers responded and committed 
to supplying a total of 3 devices for evaluation. 
Testing was completed in November 2017 and 
the tender was awarded to Dräger for the supply 
of the Dräger 7510 alcohol breath screening 
device in 2018.
Evidential Breath Alcohol Testing
The Bureau continued to support and maintain 
the 86 EvidenzerIRL instruments in Garda 
stations throughout Ireland. 
Garda Training
The Bureau provided instruction to 42 Garda 
Trainers on the operation of Dräger 7510 devices 
to enable them to further train garda personnel.
The Bureau continued to provide Operator and 
Supervisor training courses in conjunction with 
An Garda Síochána. This is a one and a half day 
training course which was devised to train Garda 
Operators and Supervisors in the use of the 
EvidenzerIRL instrument.  
A total of 122 Gardaí were trained as EBT 
Operators including 68 who were trained as 
Supervisors.
Testing EBT instruments in Garda 
Stations
Bureau Scientists tested each instrument that 
had been previously installed in Garda stations 
on at least two occasions, onsite testing was 
carried out on 200 occasions in 2018 (202 in 
2017).
This testing is an essential element in assuring 
the quality of breath alcohol test results for 
evidential purposes.
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Breath Alcohol Analysis
In 2018, a total of 6,021 drivers were brought to 
Garda Stations and provided breath specimens 
for alcohol analysis. 2.3% of these were cases 
where the EvidenzerIRL flagged a reason why the 
Section 13 certificate could not be produced, for 
example safeguards such as Mouth Alcohol or 
Breath Difference.  10% of drivers either failed 
or refused to provide breath specimens. A total 
of 5,286 breath specimens were completed with 
a Section 13 certificate issued. 
Over Twice the Limit of 22 μg 
/100ml** (Breath)
From the total of 5,286 completed breath 
specimens, 44% of these were over twice this 
limit. This is slightly higher than the blood & 
urine specimen results over twice the limit at 
40%.
**(It is important to note that on receipt of 
specimens for testing, the Bureau does not  
receive driver classification details; i.e., Fully 
Licenced Drivers versus Professional, Learner and 
Novice Drivers where the legal limits are reduced 
to 9 μg.)
Mean Alcohol Level in Breath
Excluding breath specimens which returned a 
zero alcohol result the mean certified alcohol 
level in breath was 45µg/100ml in 2018. 
Analysis of Time  
Of the total number of breath specimens (6,021) 
77% were provided between the hours of 7pm 
and 7am, 11% between 7am and 1pm and the 
remaining 12% between 1pm and 7pm.
Chart 9 Certified Breath Alcohol Levels
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0 1-9 10-22 23-35 36-44 45-66 66+
n 2017 243 320 914 941 567 1326 1201
n 2018 284 353 886 948 470 1207 1138
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Chart 10 2018 Time Breath Specimens Provided
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Gender in Evidential Breath Testing Specimens
The number of male drivers required to provide a breath specimen far exceeds the number of female 
drivers, the male to female ratio being 7:1. Five driver breath specimens did not have a date of birth 
entered, these have been excluded from the Table and Charts with age profiles below.
2018 2017
MALE 87% 86%
FEMALE 13% 14%
Table 4 Gender Profile of Breath Specimens provided
Chart 11 2018 Age Profile of Drivers- Breath
n 65+, 4% n 0-24, 12%
n 25-34, 28%
n 35-44, 27%
n 55-64, 10%
n 45-54, 19%
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Chart 12 2018 Age Profi le of Drivers - Breath  Percentage Male and Female
30%
25%
20%
15%
10%
5%
0%
0–24 25-34 35-44 45-54 55-64 65+
n % male 
(of total)
11% 24% 23% 16% 9% 4%
n % female
(of total)
1% 4% 4% 3% 1% 0.4%
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This programme is led by Principal Analyst, Dr 
Richard Maguire. The main functions of this 
programme in 2018 were:
› The analysis of blood and urine specimens for 
the presence and/or concentration of drugs.
› The issue of Certifi cates of Analysis for the 
presence and/or concentration of a drug or 
drugs.  
› Provision/maintenance of Preliminary Drug 
Testing Devices (oral fl uid) and quality 
control of consumables.
› Development of new methods of drug 
testing. 
› Provision of expert assistance to the Courts 
and Department of Transport, Tourism and 
Sport.
› Collection and analysis of data in relation to 
toxicology tests.
› Research on drugs that cause impairment in 
drivers.
The MBRS toxicology section continued to 
test all specimens under the limit for alcohol 
of 80mg/100ml in blood and 107mg/100ml in 
urine.  There were 22 over the limit specimens 
specifi cally requested by An Garda Siochána and 
14 Evidential Breath Testing negative specimens 
sent to the MBRS for drug testing. 
Roadside/Station Based Preliminary 
Drug Testing  (PDT)
The PDT program was introduced in 2017 and 
effective from 13th April 2017. This provided 
86 stationary DT5000 analysers and 47 mobile 
analysers. By the end of 2018 there were 87 
stationary analysers and 60 mobile units. The 
analyser is able to detect Cannabis, Cocaine, 
Opiates and Benzodiazepines in oral fl uid.
TOXICOLOGY PROGRAMME
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During 2018, 18 Gardaí trained in the use of the 
DT5000 to trainer level. The Bureau purchased 
4,500 consumable STKs for use with the devices 
in 2018. The Bureau also managed the quality 
control testing of the consumable cassette (STK) 
part of this system and conducted performance 
testing approximately every 6 months on each 
analyser to ensure reliable operation. The MBRS 
was satisfi ed with the performance of the 
DT5000 in 2018 and will continue to monitor its 
performance on an ongoing basis.
The number of tests on the analysers available 
to An Garda Síochána were collated for 2018; 
however, it is important to note, this is not a 
measure of enforcement activity and the current 
system does not distinguish between tests 
conducted for training, demonstration, quality 
control or enforcement purposes. The activity 
for 2018 is shown below.
ANALYSER USE TYPE NUMBER OF TESTS
Mobile 3,572
Station Based 349
Total 3,921
Table 5
When oral fluid is collected from a driver for 
testing, and is positive for a drug or drugs, the 
Bureau requests that An Garda Síochána submit 
an “Information Form” (see below) indicating 
the results of the roadside test. This is to enable 
a comparison of the performance of the DT5000 
and subsequent laboratory testing.
In all, 625 specimens were returned with 
Preliminary Drug Testing forms in 2018. Of 
these 563 were positive for at least one of 
the four drugs that the DT5000 can detect.  
Of the 563 positive cases the prevalence of 
drugs detected by the DT5000 was 408 (72% 
2018, 64% 2017) were positive for cannabis, 
230 (41% 2018, 35% 2017) were positive for 
cocaine, 45 (8% 2018, 8% 2017) were positive 
for opiates and 38 (7% 2018, 5% 2017) were 
positive for benzodiazepines. The overwhelming 
detection is for illicit drugs rather than opiates 
and benzodiazepines which can be legitimately 
purchased and/or prescribed but can also be 
misused. 
Laboratory Testing
The MBRS toxicology section continued to 
test all specimens under the limit for alcohol 
of 80mg/100ml in blood and 107mg/100ml in 
urine.  There were 2,144 specimens analysed for 
the presence of a drug or drugs which is a 34% 
increase on the number of specimens tested 
in 2017. Of these, 2,099 which were under the 
alcohol limit above were automatically tested 
for drugs. 28 specimens which were over the 
limit for alcohol above, were tested following a 
specific request from An Garda Síochána. This 
represents a 27% increase when compared 
to 2017. 17 specimens which were above the 
alcohol limit above which had been tested for 
alcohol using EBT were also tested, this is a 
factor of 3.4 times the number of the same type 
of specimens in 2017. 
Initial screening testing was conducted for 
cannabis, cocaine, opiates, methadone, 
benzodiazepines, amphetamines and 
methamphetamine. A new screening method 
based on LC-MS-MS replaced the old 
Immunoassay based ELISA test in September 
2018. While the ELISA test was fit for purpose, 
this new method, which was several years in 
development, is a significant improvement 
which will allow flexibility in adding new 
drugs and their metabolites to the MBRS 
drug panel.  This new LC-MS-MS approach 
provides information at the screening stage as 
to the specific drugs and metabolites that are 
in specimens rather than the class of drugs, 
which was the case for some drugs with the 
immunoassay.
Of the 2,144 specimens tested 1,628 (76%) 
were found to be positive for at least one drug 
class on preliminary drug testing, while 516 
(24%) were negative for the drugs targeted by 
the MBRS.  The chart below (Chart 13) shows 
the prevalence of the drugs detected in all 
specimens of blood and urine. As in previous 
years Cannabis remains the next most prevalent 
drug after alcohol, however in 2018 Cocaine has 
now replaced Benzodiazepines as the next most 
prevalent drug. The bar chart below (Chart 14) 
shows the prevalence and extent of polydrug 
use in the tested specimens for blood and urine. 
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Chart 13 Drug Prevalence from Screening Positive Specimens 2018
Chart 14 No. of classes detected per specimen 2018 
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The gender profile was 87% male and 13% female based on screening positive data and age profile of 
positive specimens is shown in chart 15 below:
Once a positive specimen is detected at 
the initial screening test, confirmation is 
carried out using Gas Chromatography with 
tandem Mass Spectrometry for Cannabis and 
Liquid Chromatography with tandem Mass 
Spectrometry for all other drugs. All specimens 
positive on lab screening in 2018 were forwarded 
for confirmation of all drugs detected at the 
screening stage, as far as specimen volume 
permitted. Previously, urine specimens requiring 
confirmation for drugs other than Cannabis and 
Benzodiazepines were sent to Eurofins (formerly 
LGC) in the UK.  This practice ceased in March 
2018 and all specimens requiring drug analysis 
after this date were tested in the Bureau’s UCD 
facility.  Only 20 urine specimens were tested by 
Eurofins in 2018. 
The workload in the area of confirmatory 
analysis has increased significantly. The overall 
increase in specimens being forwarded to 
the Bureau due to increased enforcement of 
the legislation by AGS has resulted in a 35% 
increase in screening testing. The extent of the 
increase in confirmatory testing for the various 
drugs/classes is highlighted in the tables below. 
The first table (Table 6) shows the difference in 
the number of confirmatory analyses between 
2017 and 2018 and this shows that the increase 
in confirmations was in the order of 54% across 
the board. Table 7 shows the confirmation 
rate which is calculated from the number of 
specimens which had drugs confirmed following 
positive screening in the laboratory test. 
Chart 15 Total screening positive by age 2018
n 75-84, 7
n ≥85, 1
n Not Stated, 7
n <24, 433
n 25-34, 680
n 35-44, 334
n 55-64, 42
n 65-74, 23
n 45-54, 101
DRUG CLASS 2018 2017 % Change
Cannabis 1,034 723 43%
Benzodiazepines 468 284 65%
Cocaine 535 274 95%
Opiate/Methadone 260 201 29%
Amphetamine/Methamphetamine 82 62 32%
Total 2,379 1,544 54%
Table 6
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Drug Legal Limit
∆9-Tetrahydrocannabinol (Cannabis) 1ng/ml
11-nor-9-carboxy-∆9-tetrahydrocannabinol (Cannabis) 5ng/ml
Cocaine 10ng/ml
Benzoylecgonine (Cocaine) 50ng/ml
6-acetylmorphine (Heroin) 5ng/ml
DRUG CLASS Confi rmation rate
Cannabis 92%
Benzodiazepines 93%
Cocaine 93%
Opiate/Methadone 85%
Amphetamine/Methamphetamine 85%
Table 8
Table 7
The 2016 Road Traffi c Act (enacted April 2017) introduced per se levels for Cannabis, Cocaine and Heroin 
in whole blood (see Table 8 below). 2018 was the fi rst full year of analysis and reporting under the per se 
levels. 
The number of drivers with drug results greater than or equal to the per se legal limits was 963 in 2018 
which is an increase of 186% when compared to 2017. Although the new measures only came into effect 
on the 13th of April 2017 there were 337 specimens certifi ed above the legal limit in 2017. 
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The number of drivers with drug results greater 
than or equal to the per se legal limits was 963 
in 2018 which is an increase of 186% when 
compared to 2017. Although the new measures 
only came into effect on the 13th of April 2017 
there were 337 specimens certifi ed above the 
legal limit in 2017. 
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The Medical Bureau of Road Safety maintained 
its ISO 17025 Accreditation in 2018 for the 
following areas: 
› Blood and Urine alcohol analysis
› Drug analysis
› Breath Testing analysis  
The Bureau operates a Flexible Scope; this 
facilitates the addition of new drug tests or 
changes in methods to the Bureau’s Scope 
of Accreditation as they are developed in-
house. A master list of fl exible scope changes 
is maintained as part of the fl exible scope 
procedure to record changes to accredited tests 
or add accredited tests which are in addition to 
the published Scope of Accreditation.
Two tests were added to this record in early 
2017:
Upgrade of GC-MS instrumentation to 
GC-MS-MS used in the quantitation ∆9-
Tetrahydrocannabinol and 11-nor-9-carboxy-
∆9-tetrahydrocannabinol in blood and urine 
and lowering the quantitation range of ∆9-
Tetrahydrocannabinol in blood (0.5 to 35ng/ml).
These tests and the extension to scope were 
subsequently incorporated into the Bureau’s 
Scope of Accreditation following the INAB 
visit in March 2017. Full details of the Scope of 
Accreditation are available at 
https://www.inab.ie/Directory of Accredited 
Bodies. 
QUALITY ASSURANCE
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The laboratory participates in several Profi ciency Testing schemes. 
Table 9 details the schemes for 2018.
Programme Provider Scheme No. Specimens Analytes
Toxicology CAP Drugs of Abuse in 
Whole Blood and 
Urine            
8 specimens per 
annum
Amphetamines & 
Stimulants
Cannabinoids
Cocaine & 
Metabolites
Minor Tranquilisers
Non - Opiate 
Narcotics
Opiates
Labquality Drugs of Abuse in 
Urine
6 specimens per 
annum
Amphetamines & 
Stimulants
Cannabinoids
Cocaine & 
Metabolites
Minor Tranquilisers
Non - Opiate 
Narcotics
Opiates
LGC Standards 
Profi ciency Testing
Drugs of Abuse in 
Urine
12 specimens per 
annum
Amphetamines & 
Stimulants
Cannabinoids
Cocaine & 
Metabolites
Minor Tranquilisers
Non - Opiate 
Narcotics
Opiates, Creatinine
Table 9 Profi ciency Testing Programmes
PROFICIENCY TESTING
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Programme Provider Scheme No. Specimens Analytes
LGC Standards 
Profi ciency Testing
Toxicology 8 specimens per 
annum
Amphetamines & 
Stimulants
Cannabinoids
Cocaine & 
Metabolites
Minor Tranquilisers
Non - Opiate 
Narcotics
Opiates
LGC Standards 
Profi ciency Testing
Drugs in Oral 
Fluid
12 specimens per 
annum
Amphetamines & 
Stimulants
Cannabinoids
Cocaine & 
Metabolites
Minor Tranquilisers
Non - Opiate 
Narcotics
Opiates
LGC Standards 
Profi ciency Testing
Tox- 
Benzodiazepines
8 specimens per 
annum
Diazepam, 
Nordiazepam, 
Temazepam, 
Oxazepam, 
Nitrazepam
LGC Standards Tox – Z – Drugs 8 specimens per 
annum
Zopiclone, 
Zaleplon, Zolpidem
Alcohol in Blood 
and Urine
Labquality Blood 8 specimens per 
annum
Alcohol
Labquality Urine 
Quantitative
4 specimens per 
annum
pH, Creatinine & 
Urea
LGC Standards 
Profi ciency Testing
Tox – Blood & Tox 
Urine
24 specimens per 
annum
Alcohol
Evidential Breath 
Testing
CTS, Inc. 568 Breath 
Alcohol Simulator 
Solution Analysis
2 solutions per 
annum
Alcohol
Table 12 Profi ciency Testing Programmes
The Medical Bureau of Road Safety derives its fi nances from an Annual Grant from the Department of 
Transport, Tourism and Sport. The total grant allocation for the Bureau for 2018 was €4,912,000.
FINANCIAL INFORMATION
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The Board of the Medical Bureau of Road Safety operates in accordance with the Code of Practice for 
the Governance of State Bodies. The Board is accountable to the Department of Transport, Tourism and 
Sport and the Department of Finance. The Board meets 4 times per year and is responsible for the proper 
management of the Bureau. It makes major strategic decisions and reviews the Bureau’s risk management 
strategy and control processes on an annual basis.
Board Members
The Board of the Medical Bureau of Road Safety comprises of fi ve members (including the Director) and is 
appointed by the Minister for Transport, Tourism and Sport. 
Bureau Membership and Meetings
During 2018 the Medical Bureau of Road Safety held four meetings. These meetings were held on 29th 
March, 18th July, 27th September and 6th December 2018.
Schedule of Fees and Aggregate Expenses paid to Directors during 2018
During 2018 the following fees were paid:
Name Position Attendance Record
Dr. Declan Bedford Chairman 4 of 4
Professor Denis Cusack Board Member and Director 4 of 4
Mr. Paul Burns Board Member 4 of 4
Mr. Michael Mc Dermott Board Member 3 of 3
Professor Patricia Fitzpatrick Board Member 4 of 4
Board Member Type of Fee Paid 2018 Paid 2017
Dr. Declan Bedford Fee for Chairperson of Board of State Body
Fee for Non-Executive members of Boards of State 
Bodies
€8,978
-
€6,542
€1,496
Mr. Paul Burns Fee for Non-Executive members of Boards of State 
Bodies
€5,985 €5,985
Mr. Michael Mc 
Dermott
Fee for Non-Executive members of Boards of State 
Bodies
€3,604 -
Professor Patricia 
Fitzpatrick
No Fee for Non-Executive members of Boards of State 
Bodies
- -
BOARD MEMBERS
BOARD FEES PAID
CORPORATE GOVERNANCE
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Compliance
The Board is pleased to report that during the 
year ended 31st December 2018 the Medical 
Bureau of Road Safety complied with the 
relevant provisions of the Code of Practice for 
the Governance of State Bodies. An Internal 
Audit was performed.
Disclosure
Section 22 of the Protected Disclosures Act 
2014 requires the Publication of an Annual 
Report each year relating to the number of 
protected disclosures made in the preceding 
year and any actions taken in response to such 
disclosures. Pursuant to this requirement, 
the Medical Bureau of Road Safety confi rms 
that no protected disclosures were received in 
accordance with the provisions of the Protected 
Disclosures Act, 2014 for the period from 1st 
January 2018 – 31st December 2018.
Statutory Requirements
The Medical Bureau of Road Safety confi rms 
that it complied with its statutory requirements 
during 2018.
Ethics in Public Offi ce
The members of the Board who held offi ce at 
the 31st December 2018 had no interests for the 
purposes of the Ethics in Public Offi ce Acts 1995 
and 2001.
Audit and Risk Committee
The Audit and Risk Committee reviews any 
aspect which relates to the fi nancial matters 
of the Medical Bureau of Road Safety. The 
Committee operates under formal terms 
of reference. The meetings are attended by 
members of the Committee and it reports to the 
Board four times per year.
External Financial Audit
The Comptroller and Auditor General performed 
the annual audit of the 2017 Financial 
Statements during 2018. No signifi cant issues 
were raised during the audit.
Internal Audit
The Internal Audit function is a key element in 
informing the Board on the effectiveness of the 
system of internal fi nancial control. The internal 
auditor operates in accordance with the Code of 
Practice for the Governance of State Bodies. An 
Internal Audit report was prepared in relation to 
2018.
Procurement
Competitive tendering is the normal policy 
utilized by the Medical Bureau of Road Safety 
in the procurement process. It affi rms that it 
complied with procurement procedures and 
relevant EU Directives as set out in the Code 
of Practice for the Governance of State Bodies 
during 2018.
Strategic Planning
The Bureau compiled its Annual Strategic Plan 
for 2019 and its Five-Year Strategic Plan 2019 
– 2023 and both strategies were forwarded to 
the Minister. The Plans set out the Bureau’s key 
objectives over the coming year and years in 
conjunction with its key actions to achieve these 
objectives. Both strategies can be viewed on the 
Bureau’s website.
Prompt Payment of Account
The Board acknowledges their responsibility for 
ensuring compliance in relation to the Prompt 
Payment of Accounts Act. Under an agreement 
with University College Dublin, suppliers are 
paid in the fi rst instance by the College which is 
then reimbursed by the Bureau. 
It is the policy of the Medical Bureau of Road 
Safety to ensure that all invoices are paid 
promptly. University College Dublin, as a public-
sector body, is required to comply with the 
requirements of the Act in relation to payments 
to suppliers for the supply of goods or services 
and therefore has strict procedures in place.
In the case of a small number of suppliers, 
the Bureau will issue payment by cheque 
directly to the supplier. The controls in relation 
to processing of invoices, credit notes and 
dealing with supplier disputes can only provide 
reasonable and not absolute assurance against 
material non-compliance with the Act. 
Professional Witness
The area of road safety traffi c enforcement 
and in particular driving under the infl uence 
of intoxicants, alcohol and drugs is one of the 
most litigated areas in the criminal law sphere 
in Ireland. The Bureau provides expert witness in 
cases before the Courts. In 2018 there were 10 
court attendances by Bureau staff.
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Scope of Responsibility 
On behalf of the Medical Bureau of Road Safety, 
I acknowledge the Board’s responsibility for 
ensuring that an effective system of internal 
control is maintained and operated. This 
responsibility takes account of the requirements 
of the Code of Practice for the Governance of 
State Bodies (2016). 
Purpose of the System of Internal 
Control 
The system of internal control is designed to 
manage risk to a tolerable level rather than 
to eliminate it. The system can therefore only 
provide reasonable and not absolute assurance 
that assets are safeguarded, transactions 
authorised and properly recorded and that 
material errors or irregularities are either 
prevented or detected in a timely way. 
The system of internal control, which accords 
with guidance issued by the Department of 
Public Expenditure and Reform has been in place 
in the Medical Bureau of Road Safety for the 
year ended 31 December 2018 and up to the 
date of approval of the fi nancial statements. 
Capacity to Handle Risk 
The Medical Bureau of Road Safety has an Audit 
and Risk Committee (ARC) comprising of three 
Board members.   The ARC met four times in 
2018. 
The Medical Bureau of Road Safety has also 
established an internal audit function which 
is adequately resourced and conducts a 
programme of work agreed with the ARC. 
The ARC has developed a risk management 
policy which sets out its risk appetite, the risk 
management processes in place and details the 
roles and responsibilities of staff in relation to 
risk. The policy has been issued to all staff who 
are expected to work within the Medical Bureau 
of Road Safety’s risk management policies, to 
alert management on emerging risks and control 
weaknesses and assume responsibility for risks 
and controls within their own area of work.
Risk and Control Framework 
The Medical Bureau of Road Safety has 
implemented a risk management system 
which identifi es and reports key risks and the 
management actions being taken to address 
and, to the extent possible, to mitigate those 
risks. 
A risk register is in place which identifi es the 
key risks facing the Medical Bureau of Road 
Safety and these have been identifi ed, evaluated 
and graded according to their signifi cance. 
The register is reviewed and updated by the 
ARC on an annual basis. The outcome of these 
assessments is used to plan and allocate 
resources to ensure risks are managed to an 
acceptable level. 
The risk register details the controls and actions 
needed to mitigate risks and responsibility for 
operation of controls assigned to specifi c staff. I 
confi rm that a control environment containing 
the following elements is in place: 
› procedures for all key business processes 
have been documented, 
› fi nancial responsibilities have been assigned 
at management level with corresponding 
accountability, 
› there is an appropriate budgeting system 
with an annual budget which is kept under 
review by senior management, 
›  there are systems aimed at ensuring 
the security of the information and 
communication technology systems, 
› there are systems in place to safeguard the 
assets, and 
› control procedures over grant funding to 
outside agencies ensure adequate control 
over approval of grants and monitoring and 
review of grantees to ensure grant funding 
has been applied for the purpose intended. 
STATEMENT ON INTERNAL 
CONTROL
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Ongoing Monitoring and Review 
Formal procedures have been established 
for monitoring control processes and control 
defi ciencies are communicated to those 
responsible for taking corrective action and to 
management and the Board, where relevant, in a 
timely way. I confi rm that the following ongoing 
monitoring systems are in place: 
› key risks and related controls have been 
identifi ed and processes have been put in 
place to monitor the operation of those 
key controls and report any identifi ed 
defi ciencies, 
› reporting arrangements have been 
established at all levels where responsibility 
for fi nancial management has been assigned, 
and 
› there are regular reviews by senior 
management of periodic and annual 
performance and fi nancial reports which 
indicate performance against budgets/
forecasts.
Procurement 
I confi rm that the Medical Bureau of Road Safety 
has procedures in place to ensure compliance 
with current procurement rules and guidelines 
and that during 2018 the Medical Bureau of 
Road Safety complied with those procedures.
Review of Effectiveness 
I confi rm that the Medical Bureau of Road Safety 
has procedures to monitor the effectiveness of 
its risk management and control procedures. 
The Medical Bureau of Road Safety’s monitoring 
and review of the effectiveness of the system 
of internal fi nancial control is informed by the 
work of the internal and external auditors, 
the Audit and Risk Committee which oversees 
their work, and the senior management within 
the Medical Bureau of Road Safety responsible 
for the development and maintenance of the 
internal fi nancial control framework. 
I confi rm that the Board conducted an annual 
review of the effectiveness of the internal 
controls for 2018. 
Internal Control Issues 
No weaknesses in internal control were 
identifi ed in relation to 2018 that require 
disclosure in the fi nancial statements. 
Tax Compliance
The Medical Bureau of Road Safety is committed 
to compliance with taxation laws and was 
compliant during 2018.
On behalf of the Board of the Medical Bureau of 
Road Safety:
Dr. Declan Bedford
Chairman
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The Bureau continued during 2018 to operate within its Employment Control Framework complement. 
During 2018 the Bureau received three requests which were dealt with as follows:
Decision Number of Requests
Granted 1
Administrative Pathway 2
Total 3
Category of Requester Number Received
Journalist 1
Solicitor 1
Other 1
Total 3
STAFFING  
FREEDOM OF INFORMATION
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Director
Alcohol 
Principal 
Analyst
Quality 
Manager 
Prinipal
Analyst
IT Offi cer
Toxicology 
Principal 
Analyst
Snr Admin 
Offi cer
Analyst x5 Laboratory Attendant
Operations 
Support 
Specialist
Analyst x6
Snr Executive 
Assistant
Chief
Analyst
Senior 
Analyst x4
Senior 
Technical 
Offi cer
Technical 
Offi cer
Senior 
Analyst x4
Admin
Offi cer
Snr Executive 
Assistant
Executive 
Assistant
Snr Executive 
Assistant
Executive 
Assistant
Executive 
Assistant
MEDICAL BUREAU OF ROAD SAFETY
ORGANISATION CHART
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1 The Chief Analyst and two Senior Analysts attended the joint annual Meeting of SOFT and 
TIAFT at Boca Raton, Florida from 7th - 11th January 2018. (Rescheduled from 2017)
2 The Quality Manager attended a two day UCD People Management Programme on 30th - 31st 
January 2018 in UCD.
3 The Director was a guest speaker at Educational Meetings in the Irish College of General 
Practitioners on 6th February (Wexford), 17th February (Dublin) and 12th April 2018 (Cavan).
4 A Principal Analyst and a Senior Analyst attended the OIML meeting in Warsaw, Poland from 
14th of February 2018 for 5 and 2.5 days, respectively.
5 An Administrative Offi cer attended a two day UCD People Management Programme on 27th 
February and 20th March 2018 in UCD.
6 An Analyst attended the UKIAFT LTG meeting on 09th March 2018 in London.
7 The Director was a guest speaker at a 1 day seminar of the International Road Victims 
Association in Mullingar, Co. Westmeath on 18th March 2018.
8 The Director attended a meeting of the Medical Advisory Panel on Alcohol, Drugs and Driving, 
UK  in the Department of Transport, London on 21st March 2018.
9 An IT Offi cer attended the AD IT Security seminar on 22nd March 2018 in Ballsbridge, Dublin.
10 The Senior Administrative Offi cer, an Administrative Offi cer, Senior Executive Assistant and 
Executive Assistant attended the CMG GDPR Conference on 11th April 2018 in the Stillorgan 
Park Hotel, Dublin.
11 The Director attended a RCPI Working Group on Traffi c Medicine in the RCPI, Dublin on 12th 
April 2018.
12 A Principal analyst attended the International Association of Chemical Testing conference from 
29th April 2018 for 6 days in Indianapolis, USA.
13 A Principal Analyst and two Analysts attended the one day Irish Mass Spectrometry Society 
conference on 09th May 2018 in the Red Cow Hotel, Dublin.
14 The Director attended a 2 day International Faculty of Forensic and Legal Medicine Conference 
in the RCP, London from 10th - 12th May 2018.
15 An Analyst attended a 6 day Borkenstein Alcohol Course from 13th May 2018 in Indiana 
University, USA.
16 An Analyst attended a two day Eurochem workshop on 14th and 15th May 2018 in Dublin 
Castle, Dublin.
17 A Senior Administrative Offi cer and an Administrative Offi cer attended a course on the Role of 
the Data Protection Offi cer at CMG Training on 14th May 2018, Sandyford, Dublin.
18 An Analyst and a Laboratory Assistant attended Mask Face Fitting Training on 22nd May 2018 
at UCD SIRC, UCD.
Courses and Conferences attended by staff in 2018
COURSES AND CONFERENCES 
ATTENDED BY STAFF IN 2018
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19 A Senior Technical Officer attended a one day PAT Testing course on 24th May 2018 at the 
National Enterprise Park, Portlaoise, Co. Laois
20 An Analyst attended a one day Agilent GC/GCMS User Meeting on 24th May 2018 at Teagasc, 
Dublin.
21 The Director was a guest speaker at the International Academy of Legal Medicine International 
Conference in Fukuora, Japan from 5th – 8th June 2018. 
22 The Director attended the Annual Conference in the Irish College of General Practitioners as a 
guest speaker on 25th May 2018.
23 A Senior Analyst attended a one day meeting of the UK and Ireland Association of Forensic 
Toxicologists on 28th June 2018 at Charing Cross, London.
24 The Director was a guest speaker at the Road Safety Authority meeting on 25th July 2018.
25 A Senior Analyst attended the five day TIAFT 2018 conference from 26th - 30th August 2018 in 
Ghent, Belgium. 
26 The Director was a guest speaker at the International Council on Alcohol, Drugs and Traffic 
Safety in Prague, Czech Republic from 1st – 4th September 2018. 
27 The Director attended the Coroners Society of Ireland Meeting in Portlaoise from 7th – 8th 
September 2018.
28 The IT Officer attended the three day Thermo Fisher launch from 10th - 12th September 2018 
in Berlin, Germany.
29 A Technical Officer and two Analysts attended a half-day Manual Handling training course on 
18th September 2018 in UCD.
30 A Principal Analyst/Quality Manager attended a Chemistry Network meeting on 19th 
September 2018 in Kildare.
31 A Principal Analyst attended a 3 day EvidenzerIRL User Group meeting from 1st - 3rd October 
in Sweden.
32 A Principal Analyst attended a five day conference of the Society of Forensic Toxicologists from 
7th - 12th October in Minneapolis, Minnesota, USA
33 The Director attended a RCPI Working Group on Traffic Medicine in the RCPI, Dublin on 8th 
October 2018.
34 The Director attended a meeting of the Medical Advisory Panel on Alcohol, Drugs and Driving, 
UK  in the Department of Transport, London on 17th October 2018.
35 The Director and staff of the Medical Bureau of Road Safety attended an Academic Meeting on 
18th October 2018 to mark the occasion of the 50th Anniversary.
36 The Quality Manager attended the Paradigm User Group Meeting on 23rd October 2018 in 
Celbridge, Co. Kildare.
37 11 staff attended Dräger 7510 training on 24th October 2018 at the MBRS. 
38 A Principal Analyst and a Senior Analyst attended a two day UKIAFT annual conference on 1st - 
2nd November 2018 at the Hilton Kilmainham, Dublin.
39 Two Analysts attended the AGM of UKIAFT on 2nd November 2018 at the Hilton, Kilmainham, 
Dublin.
40 An Analyst attended Agile Yellow Belt training on 28th November 2018 at Ardmore Annex, 
UCD.
41 An Analyst attended a 2 day conference on New Psychoactive Substances 2018 on 29th-30th 
November 2018 in London.
Courses and Conferences attended by staff in 2018
Under the Government’s commitment to 
improve public energy effi ciency by 33% in 
2020 the Medical Bureau of Road Safety has 
registered for and is reporting through the SEAI 
online system.  The Bureau’s main energy usage 
is gas and electricity which is necessary for 
operating a forensic laboratory and ancillary 
facilities, e.g. heating and lighting, laboratory 
equipment, air handling, computers and servers. 
The Bureau utilizes initiatives to improve 
energy effi ciency.  A Building Management 
System (BMS) is used to monitor and control 
heating, air handling units, water boiler (direct 
hot water supply) and extractor fans. Each 
of the four fl oors of the Bureau’s premises is 
managed individually and automatic controls 
are scheduled accordingly. Energy effi cient light 
bulbs, movement sensors and timer switches 
have been fi tted throughout the building to 
further reduced energy consumption.
The Medical Bureau of Road Safety has been 
further liaising with UCD Building and Services 
to decrease energy consumption and plans 
to implement a major lighting upgrade of the 
facility in 2019.
The descriptions and statistics contained within this report are of a condensed and general informative 
nature only.  They should not, by themselves, be relied upon in determining legal rights or other 
decisions under the Road Traffi c Acts. Readers and users are advised to verify with their legal advisors any 
information on which they may wish to rely. 
Professor Denis A. Cusack, Dr. Declan Bedford,
Director. Chairman.
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